Public-registry site landscape for NCT06927986, a EGFR-mutated Locally Advanced or Metastatic NSCLC study sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06927986 (registry record) |
| Sponsor | CSPC Megalith Biopharmaceutical Co.,Ltd. |
| Condition(s) | EGFR-mutated Locally Advanced or Metastatic NSCLC |
| Phase | PHASE3 |
| Listed sites | 1 |
| Site countries | China |
At Shanghai Chest Hospital — one of the facilities listed on this trial — 7 other studies are actively recruiting EGFR-mutated Locally Advanced or Metastatic NSCLC patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT06927986 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →